Aza-bicycloalkyl ethers and their use as alpha7-nAChR agonists

Details Aza-bicycloalkyl ethers and their use as alpha7-nAChR agonists Aza-bicycloalkyl ethers and their use as alpha7-nAChR agonists

2007-06-26

2009-08-25

Berch, Mark L (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C546S137000, C546S183000, C546S276700, C544S238000, C544S315000, C514S339000

Reexamination Certificate

active

07579362

ABSTRACT:
The present invention relates to 1-aza-bicycloalkyl derivatives of formula I,wherein X is CH2or a single bond; Y is a group of formulaand wherein R has the meanings as defined in the specification, which compounds are alpha 7 nicotinic acetylcholine receptor (nAChR) agonists;to processes for their production, their use as pharmaceuticals and to pharmaceutical compositions comprising them.

REFERENCES:
patent: 4921860 (1990-05-01), Cliffe
patent: 5385912 (1995-01-01), Neuenschwander et al.
patent: 5494918 (1996-02-01), Neuenschwander et al.
patent: 5612352 (1997-03-01), Brown et al.
patent: 0149088 (1989-01-01), None
patent: 0 306 148 (1989-03-01), None
patent: 0370415 (1989-11-01), None
patent: 0458214 (1991-05-01), None
patent: 2208385 (1988-08-01), None
patent: 06-293768 (1994-10-01), None
patent: 08-502481 (1996-03-01), None
patent: 2002-030084 (2002-01-01), None
patent: 9215579 (1992-09-01), None
patent: 9321184 (1993-10-01), None
patent: WO 94/08992 (1994-04-01), None
patent: 9531458 (1995-11-01), None
patent: 9711072 (1997-03-01), None
patent: WO 99/03859 (1999-01-01), None
patent: WO 01/29034 (2001-04-01), None
patent: 0160821 (2001-08-01), None
patent: WO 01/85727 (2001-11-01), None
patent: WO 02/15662 (2002-02-01), None
patent: 03051874 (2003-06-01), None
patent: 2004016608 (2004-02-01), None
patent: 03037896 (2008-05-01), None
Lubin, et al., Annals N. Y. Acad. Sci., 628-632, 1999.
Plummer, et al., Respiratory Research, 2005, 6:29.
Salamone, et al., McGill J. Med., 2000, 5:90-97.
Kalamida, et al., FEBS Journal, 274 (2007), 3799-3845.
Martha U. Gillette et al., Role of the M1 Receptor In Regulating Circadian Rhythms, Life Sciences 68, 2001, pp. 2467-2472, Elsevier Science Inc., USA.
Sandrine N. Hardouin et al.; Altered Cardiovascular Reponses in Mice Lacking the M1 Muscarinic Acetylcholine Receptor, The Journal of Pharmacology and Experimental Therapeutics, 2002, pp. 129-137, vol. 301, No. 1, The American Society for Pharmacology and Experimental Therapeutics, USA.
Malcolm J. Sheardown, Muscarinic M1 Receptot Agonists and M2 Receptor Antagonists as Therapeutic Targets in Alzheimer's Disease, Expert Opin. Ther. Patents, 2002, pp. 863-870, Ashley Publications.
Harumi Kitagawa et al., Safety, Pharmacokinetics, and Effect on Cognitive Function of Multiple Doses of GTS-21 in Healthy, Male Volunteers, Neuropsychopharmacology, 2003, pp. 542-551, 28, Nature Publishing Group.

Affiliated with

Also associated with

Rating

Aza-bicycloalkyl ethers and their use as alpha7-nAChR agonists does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Aza-bicycloalkyl ethers and their use as alpha7-nAChR agonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Aza-bicycloalkyl ethers and their use as alpha7-nAChR agonists will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4077623